# Imatinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/imatinib

> The next catalyst for imatinib, sponsored by Inhibikase Therapeutics, Inc. (IKT), is its interim data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for imatinib?

The next catalyst for imatinib, sponsored by Inhibikase Therapeutics, Inc. (IKT), is its interim data readout, 1H 2027. Press release filed with the SEC (EX-99): "An interim safety readout for Part A of the Phase 3 IMPROVE-PAH study (n=50) is planned for the first half of 2027." [Calendar and source filings](https://sec-api.dev/pdufa/imatinib)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-455560, https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/d95716dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/imatinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | imatinib |
| Codes | IKT-001, TNX-201 |
| Sponsor | Inhibikase Therapeutics, Inc. (IKT) https://sec-api.dev/companies/ikt/catalysts |
| Indications |  |
| Modality | small_molecule |
| FDA designations | orphan, priority review |

## Timeline

### Jun 2024: topline data readout

- Status: completed, missed. Date confidence: month. Stage: 2.
- First seen 2025-03-27, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0000950170-25-046096): "For example, in June 2024, Aerovate Therapeutics developing an inhaled imatinib product candidate for PAH announced topline Phase 2b clinical trial results indicating the trial did not meet its primary endpoint for improvement in pulmonary vascular resistance versus placebo." https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm

### Nov 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-03-27, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0000950170-25-046096): "While in November 2024, the Company received authorization for its Phase 2 trial (702 trial) for IKT-001 for PAH, in addition to our already commenced Phase 1 and Phase 2 clinical trials and our two-part dose finding/dose equivalence study for IKT-001, we could encounter problems that could halt our planned clinical trials or require us to repeat such clinical trials." https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm

### Q4 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-08-14, last confirmed 2025-11-20.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-289768): "Initiation of IKT's Phase 3 Study in PAH Projected Events st Expected 1 Site Activation in Phase 3 IMPROVE-PAH Study (IKT- ✓ 1H 2024 FDA Pre-IND for IKT-001 in PAH Q4 2025 / Q1 001 for Measuring Pulmonary Vascular Resistance and Outcome" https://www.sec.gov/Archives/edgar/data/1750149/000119312525289768/d20255dex991.htm
- SEC Form 8-K (accession 0001193125-25-289768): "Given the Company was well-advanced in initiating the previous Phase 2b study design, the Company expects to initiate IMPROVE-PAH in the first quarter of 2026, with this study expected to be conducted in up to approximately 180 sites around the world." https://www.sec.gov/Archives/edgar/data/1750149/000119312525289768/d20255d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-180889): "IKT-001 toward a late-stage clinical trial in PAH, said Mark Iwicki, Chief Executive Officer of Inhibikase. We have now finalized our study protocol, and we expect to initiate our Phase 2b clinical study of IKT-001, our re-engineered prodrug of imatinib mesylate, in PAH in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1750149/000119312525180889/d946023dex991.htm

### May 12, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-05-12, last confirmed 2026-05-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-219610): ""Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended March 31," https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/d119997dex991.htm

### August 11, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-08-11, last confirmed 2026-08-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-344623): ""Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments." https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/d134059dex991.htm

### November 10, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-11-10, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-455560): ""Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended September 30, 2026, and highlighted recent developments." https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/d95716dex991.htm

### 1H 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-11-10, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-455560): "An interim safety readout for Part A of the Phase 3 IMPROVE-PAH study (n=50) is planned for the first half of 2027." https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/d95716dex991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/imatinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Imatinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/imatinib

```bibtex
@misc{secapidev_pdufa_imatinib_20261116,
  title        = {Imatinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/imatinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_imatinib_20261116","title":"Imatinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/imatinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
